Parasitic Organism Or Component Thereof Or Substance Produced By Said Parasitic Organism (e.g., Schistosoma, Dirofilaria, Trichinella, Fasciola, Ancylostoma, Ascaris, Etc.) Patents (Class 424/265.1)
  • Patent number: 9918989
    Abstract: The present disclosure provides methods for treating or preventing malaria by administration of a protein kinase inhibitor and optionally one or both of a further protein kinase inhibitor and an antimalarial drug to a mammalian subject infected with or at risk of exposure to Plasmodium sp. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in mosquitoes feeding on recipients of the regimens. Additionally, the present disclosure provides methods for screening candidate antimalarial agents.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 20, 2018
    Assignee: The Regents Of The University Of California
    Inventors: Shirley Luckhart, Cecilia Giulivi
  • Patent number: 9255140
    Abstract: The present disclosure relates to a method for inducing an antigen-specific immune response to an antigen in a mammal in need thereof, or potentiating an immune response, by administering to the mammal an effective amount of an isolated Ov-ASP, or at least one subunit of Ov-ASP.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: February 9, 2016
    Assignee: NEW YORK BLOOD CENTER, INC.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 9248169
    Abstract: No effective vaccine exists for the devastating parasitic disease of Schistosomiasis. The present invention focuses on Sm-p80, a functionally important antigen of Schistosoma mansoni that plays a pivotal role in the schistosome immune evasion process. When used in a novel vaccine formulation, Sm-p80 demonstrates consistent immunogenicity, protective potential, and antifecundity effects. Two novel DNA constructs were made for immunization purposes. Sm-p80 coding sequence was cloned into VR 1020. Additionally, Sm-p80 coding sequence was cloned into pcDNA3.1 with flanking CpG motifs on each end of the Sm-p80 sequence. When used in different vaccine formulations, both of the constructs demonstrate the superior antifecundity and anti-worm effects of Sm-p80, which has great potential as an important vaccine candidate for the reduction of the morbidity associated with schistosome infection.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: February 2, 2016
    Assignee: Texas Tech University System
    Inventors: Afzal A. Siddiqui, Gul Ahmad, Weidong Zhang
  • Patent number: 9212220
    Abstract: Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a mammalian sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: December 15, 2015
    Assignees: Idexx Laboratories, Inc., Divergence, Inc.
    Inventors: David Allen Elsemore, Laurie A. Flynn, Michael Crawford, Jinming Geng
  • Publication number: 20150125488
    Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,
    Type: Application
    Filed: December 30, 2014
    Publication date: May 7, 2015
    Applicant: VALNEVA AUSTRIA GMBH
    Inventors: WALTER SCHMIDT, KAREN LINGNAU, CAROLA WENANDER, ALENA EGYED
  • Patent number: 9017699
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 28, 2015
    Assignee: New York Blood Center, Inc.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Patent number: 8986703
    Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 24, 2015
    Assignee: PepTcell, Ltd.
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley
  • Publication number: 20150079134
    Abstract: The invention relates to a field of tissue repair and regeneration. More particularly, the invention relates to a composition for promoting cutaneous wound healing. In one embodiment, the composition is composed of one or more metazoan parasites or a mimic thereof sufficient to promote helminth-induced type-2 immune response. Preferably, the composition contains N. brasiliensis excretory/secretory antigen (NES) or an immune triggering portion thereof. The invention also relates to a method of accelerating wound healing in a subject in need of such treatment.
    Type: Application
    Filed: March 18, 2014
    Publication date: March 19, 2015
    Applicant: Rutgers, The State University of New Jersey
    Inventors: William C. Gause, Fei Chen, Zhugong Liu, Pankaj Mishra
  • Publication number: 20150071960
    Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: Chi-Huey WONG, Alice L. Yu, Kun-Hsien Lin, Tai-Na Chen
  • Publication number: 20150064727
    Abstract: Ectoparasite infestation of a substrate like bedding is detected by contacting a sample from the substrate with a polyclonal ectoparasite antibody generated from a whole ectoparasite immunogen, under conditions wherein the antibody specifically binds ectoparasite antigen in the sample.
    Type: Application
    Filed: February 27, 2013
    Publication date: March 5, 2015
    Inventors: Rajeev Vaidyanathan, Joseph Perrone, Ellen Braulieu, Scott Fields
  • Patent number: 8962265
    Abstract: Cloning and characterization of a TgIF2? kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2? kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2? phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2? mutant (S71A substitution) exhibited loss of eIF2? kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2? phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: February 24, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventors: William J. Sullivan, Jr., Ronald C. Wek
  • Publication number: 20150030682
    Abstract: Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a virus, bacteria, fungus or parasite.
    Type: Application
    Filed: October 8, 2014
    Publication date: January 29, 2015
    Inventors: Thomas J. Powell, James Gorham Boyd
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Patent number: 8840899
    Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: September 23, 2014
    Assignee: Emory University
    Inventors: Rafi Ahmed, Christian P. Larsen, Koichi Araki
  • Publication number: 20140242153
    Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 28, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
  • Publication number: 20140242113
    Abstract: This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus preparation) and a liquid edible oil composition (e.g., a liquid edible oil composition containing one or more medium chain triglycerides) are provided. In some cases, liquid vaccine preparations that include a buffer component (e.g., CaCO3) are provided.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 28, 2014
    Inventor: Leonard P. Ruiz, JR.
  • Publication number: 20140212452
    Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.
    Type: Application
    Filed: March 20, 2014
    Publication date: July 31, 2014
    Inventors: Felicito Guerrero, Adalberto A. Perez de Leon
  • Publication number: 20140212500
    Abstract: Compositions containing sterilized antigens with a high diversity, which can be collected from primitive jungle areas, and uses thereof for balancing immune responses and treating immunological diseases in a subject.
    Type: Application
    Filed: August 23, 2012
    Publication date: July 31, 2014
    Applicant: Academia Sinica
    Inventor: Tse Wen Chang
  • Patent number: 8734807
    Abstract: Schistosomiasis mansoni is caused by flukes called Schistosoma(es) that enters the human body through the skin in Schistosoma infested waters. The Schistosomes travel from the skin into human blood vessels where they mate, produce antigen containing eggs that travel from the blood vessels into the small intestines, where they are released in the human feces. Male and female Schistosome mates in human blood vessels, male Schistosomes secrete a protein called TGR ? protein to the Trk receptor sites on the females Schistosomes membranes. The process stimulates the formation of chemical SmInAct in female Schistosomes, a chemical necessary for the female Schistosomes to produce eggs. This novel technique describes new methods to inhibit Trk receptor sites on female Schistosome membranes using Trk inhibitor agent to prevent TGR ? proteins from binding to the Trk receptor sites. Thus, preventing SmInAct from being created in female Schistosomes, preventing production of eggs and Schistosomiasis.
    Type: Grant
    Filed: April 6, 2013
    Date of Patent: May 27, 2014
    Inventor: Gabriel Langlois-Rahme
  • Patent number: 8728492
    Abstract: Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the Plasmodium falciparum circumsporozoite protein (CSP) known to contain CD4 and CD8 T cell epitopes, and include both epitopes from highly variable and highly conserved regions of CSP.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: May 20, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Avigdor Shafferman, Anat Zvi, John Fulkerson, Jerald C. Sadoff
  • Patent number: 8722063
    Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: May 13, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Felicito Guerrero, Jr., Adalberto A. Perez de Leon
  • Publication number: 20140127301
    Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 8, 2014
    Applicants: Massachusetts Institute of Technology, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Frank Alexis, Matteo Iannacone, Jinjun Shi, Pamela Basto, Elliott Ashley Moseman, Ulrich von Andrian, Robert S. Langer, Omid C. Farokhzad, Elena Tonti
  • Patent number: 8715697
    Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 6, 2014
    Assignees: Institut Pasteur de Tunis, Institut Pasteur
    Inventors: Yosser Ben Achour, Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
  • Publication number: 20140120139
    Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 1, 2014
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria A. Croyle, Jin Huk Choi, Stephen Schafer
  • Patent number: 8709445
    Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: April 29, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
  • Patent number: 8703147
    Abstract: The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The compositions include various antigens of Plasmodium falciparum, both alone and in combination. The invention further includes fragments of the antigens.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: April 22, 2014
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Alan Cowman, James Beeson, Alexander Gerd Maier, Kristina E. M. Persson, Jonathan S. Richards, Sash Lopaticki
  • Patent number: 8647643
    Abstract: The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response.
    Type: Grant
    Filed: September 26, 2009
    Date of Patent: February 11, 2014
    Assignee: Cadila Pharmaceuticals, Ltd
    Inventors: Bakulesh Mafatlal Khamar, Indravadan Ambalal Modi, Rajiv Indravadan Modi
  • Patent number: 8637046
    Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: January 28, 2014
    Assignees: Cornell University, Novartis AG
    Inventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
  • Patent number: 8629260
    Abstract: The present disclosure provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present disclosure also provides compositions for vaccines to prevent Leishmaniasis.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: January 14, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Jesus G. Valenzuela, Yasmine Belkaid, Shaden Kamhawi, David Sacks, Jose M.C. Ribeiro
  • Publication number: 20130315947
    Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 28, 2013
    Inventors: Felicito Guerrero, JR., Adalberto A. Perez de Leon
  • Publication number: 20130302278
    Abstract: Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/or TLR agonist).
    Type: Application
    Filed: April 16, 2013
    Publication date: November 14, 2013
    Inventors: Randolph J. Noelle, Ross M. Kedl, Cory L. Ahonen
  • Publication number: 20130295147
    Abstract: Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells.
    Type: Application
    Filed: December 21, 2011
    Publication date: November 7, 2013
    Applicant: BRACCO SUISSE S.A.
    Inventors: Gilles Bioley, Blaise CH Corthesy, Philippe Bussat, Anne Lassus, Michel Schneider
  • Patent number: 8563008
    Abstract: The disclosure provides novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including the sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to their for treating gestational malaria. Diagnostic methods and kits are described.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: October 22, 2013
    Assignees: Institut de Recherche pour le Development (IRD), Institut Pasteur
    Inventors: Philippe Lucien Deloron, Nicaise George Tuikue Ndam, Gwladys Irénée Bertin, Peter David, Emmanuel Bischoff, Caroline Stéphanie Proux, Jean-Yves Coppee, Ali Salanti, Thomas Lavstsen
  • Publication number: 20130273111
    Abstract: The polynucleotide encoding the antigen Wb123 from the filarial nematode Wuchereria bancrofti, the major causative organism of lymphatic filariasis is provided, along with the polypeptide encoded by the polynucleotide. Methods for making the WM23 antigen, recombinant vectors encoding the Wb123 polynucleotide, and methods of detection of the Wb123 antigen through luciferase immunprecipitation, ELISA and other detection systems are also provided.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 17, 2013
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Thomas B. Nutman, Doran Fink, Joseph Kubofcik, Peter D. Burbelo
  • Patent number: 8551500
    Abstract: The invention concerns an immunogenic composition comprising: i) an antigenic polypeptide consisting of a fragment of the protein histone H2B of Leishmania, said fragment including the N-terminal region of said protein histone H2B, and ii) an adjuvant stimulating the immune response.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: October 8, 2013
    Assignees: Institut Pastuer, Institut Pasteur De Tunis
    Inventors: Mehdi Chenik, Hechmi Louzir, Koussay Dellagi
  • Publication number: 20130259898
    Abstract: Disclosed are compositions and the use of the compositions for protection against pathogens comprising an isolated internal pathogenic protein, a TLR agonist and an aluminum salt.
    Type: Application
    Filed: November 9, 2010
    Publication date: October 3, 2013
    Applicant: NATIONAL JEWISH HEALTH
    Inventors: Megan Macleod, Amy McKee, John W. Kappler, Philippa Marrack
  • Publication number: 20130259946
    Abstract: Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a virus, bacteria, fungus or parasite.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 3, 2013
    Applicant: ARTIFICIAL CELL TECHNOLOGIES, INC.
    Inventors: Thomas J. Powell, James Gorham Boyd
  • Publication number: 20130243841
    Abstract: A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 19, 2013
    Applicant: Novartis AG
    Inventors: Sushma Kommareddy, Derek O'Hagan, Manmohan Singh, Amanda Scampini Bonificio, Barbara Baudner
  • Publication number: 20130236490
    Abstract: The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a combination thereof.
    Type: Application
    Filed: November 7, 2011
    Publication date: September 12, 2013
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Ramaswamy Kalyanasundaram
  • Publication number: 20130230551
    Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.
    Type: Application
    Filed: December 20, 2012
    Publication date: September 5, 2013
    Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung NG
  • Publication number: 20130216580
    Abstract: Described are methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite, preferably P.
    Type: Application
    Filed: September 7, 2011
    Publication date: August 22, 2013
    Inventors: Ariane Rodriguez-Munoz, Katarina Radosevic, Angelique Alida Corina Lemckert
  • Publication number: 20130195923
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 1, 2013
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Publication number: 20130195910
    Abstract: The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.
    Type: Application
    Filed: March 11, 2013
    Publication date: August 1, 2013
    Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventor: University of Georgia Research Foundation, Inc.
  • Publication number: 20130195968
    Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
    Type: Application
    Filed: July 6, 2011
    Publication date: August 1, 2013
    Applicant: Novartis AG
    Inventors: Andrew Geall, Christian Mandl, Derek O'Hagan, Manmohan Singh
  • Publication number: 20130183339
    Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicant: Intercell AG
    Inventor: Intercell AG
  • Publication number: 20130177640
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Application
    Filed: June 7, 2011
    Publication date: July 11, 2013
    Applicant: NOVARTIS AG
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
  • Publication number: 20130177639
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 11, 2013
    Applicant: NOVARTIS AG
    Inventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Mandl
  • Publication number: 20130171192
    Abstract: A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox and anthrax.
    Type: Application
    Filed: October 23, 2012
    Publication date: July 4, 2013
    Applicant: IRX Therapeutics, Inc.
    Inventor: IRX Therapeutics, Inc.
  • Patent number: 8470343
    Abstract: The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPI”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the Plasmodium falciparum GPI inositolglycan domain or its derivatives. The present invention is useful, inter alia, as a prophylactic and/or therapeutic treatment for disease conditions such as, for example, infection by parasites and in particular infection by Plasmodium species.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: June 25, 2013
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventor: Louis Schofield
  • Publication number: 20130149375
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg.
    Type: Application
    Filed: July 6, 2011
    Publication date: June 13, 2013
    Inventor: Andrew Geall